---
phase: 03-peptide-science
plan: 01
subsystem: ui
tags: [peptides, pubmed, education, research, bpc157, tb500, semaglutide, ipamorelin, epithalon]

# Dependency graph
requires:
  - phase: 01-foundational-physiology
    provides: exercise-protocols section with Baar tendon protocol (cross-reference target)
  - phase: 02-cognitive-science
    provides: nback-working-memory section (cross-reference target for GHK-Cu in plan 02)
provides:
  - 12 verified PubMed studies for BPC-157, TB-500, Semaglutide, Ipamorelin, Epithalon in app/education/page.tsx
  - All 8 fabricated PMIDs removed from peptide-science section
  - crossReferences to exercise-protocols wired on 6 studies
  - Section description updated to reflect full 9-peptide scope
affects:
  - 03-02: Plan 02 appends remaining 11 studies (GHK-Cu, DSIP, MOTS-c, 5-Amino-1MQ) to this section
  - 03-03: Plan 03 updates practicalApplication with full cross-reference text

# Tech tracking
tech-stack:
  added: []
  patterns:
    - "Verified PubMed study pattern: each study has pmid field + link field pointing to pubmed.ncbi.nlm.nih.gov/{PMID}/"
    - "Evidence tier honest framing: preclinical/animal/cell vs Phase 3 RCT — stated explicitly in keyFindings"
    - "crossReferences array links study to downstream section IDs (exercise-protocols)"

key-files:
  created: []
  modified:
    - app/education/page.tsx

key-decisions:
  - "All 8 fabricated PMIDs removed: 37456789 (ipamorelin/motsc duplicate), 35789234 (bpc157), 37891234 (tb500), 38123456 (epithalon), 36789456 (dsip), 35678912 (ghkcu), 38567890 (5amino1mq)"
  - "Study ordering: BPC-157 (3) → TB-500 (2) → Semaglutide (2) → Ipamorelin (2) → Epithalon (3) — highest-priority cross-reference peptides first"
  - "Section description updated to name all 9 peptides explicitly by category grouping"
  - "practicalApplication left unchanged — Plan 03 will update it with full cross-reference text"
  - "bpc157-2 and bpc157-3 lack crossReferences (no exercise-protocol synergy text in relevance)"
  - "epithalon-1/2/3 lack crossReferences (anti-aging focus, no direct exercise synergy)"
  - "tb500-2, semaglutide-1 have crossReferences — sarcopenia risk framing for semaglutide-1 critical"

patterns-established:
  - "Evidence tier pattern: 'Animal study (rat); human clinical trials not published' in keyFindings for preclinical-only peptides"
  - "Sarcopenia risk cross-reference: semaglutide studies explicitly flag muscle loss and require exercise-protocols link"
  - "Independent replication caveat: epithalon studies note single Khavinson group — no independent replication"

requirements-completed:
  - PEPT-01
  - PEPT-02
  - PEPT-03
  - PEPT-04

# Metrics
duration: 3min
completed: 2026-03-19
---

# Phase 3 Plan 01: Peptide Science (Batch 1) Summary

**12 verified PubMed studies replacing 8 fabricated entries for BPC-157, TB-500, Semaglutide, Ipamorelin, and Epithalon — all fabricated PMIDs eliminated, exercise-protocol cross-references wired on 6 studies**

## Performance

- **Duration:** 3 min
- **Started:** 2026-03-19T12:56:28Z
- **Completed:** 2026-03-19T12:59:34Z
- **Tasks:** 1 completed
- **Files modified:** 1

## Accomplishments

- Removed all 8 fabricated PMIDs (37456789, 35789234, 37891234, 38123456, 36789456, 35678912, 38567890) — zero remain
- Inserted 12 verified PubMed studies across 5 peptides (BPC-157 x3, TB-500 x2, Semaglutide x2, Ipamorelin x2, Epithalon x3)
- Wired `crossReferences: ["exercise-protocols"]` on bpc157-1, tb500-1, semaglutide-1, semaglutide-2, ipamorelin-1, ipamorelin-2 (6 cross-links satisfying PEPT-04)
- Updated section description to mention all 9 therapeutic peptides by name with category groupings
- TypeScript compiles without errors; 194 lines inserted / 98 removed

## Task Commits

Each task was committed atomically:

1. **Task 1: Replace fabricated peptide studies with 12 verified studies** - `d59ae13c` (feat)

**Plan metadata:** committed with SUMMARY.md below

## Files Created/Modified

- `app/education/page.tsx` — Peptide-science section: 8 fabricated studies replaced by 12 verified; section description updated

## Decisions Made

- Study ordering reflects cross-reference priority: highest-synergy peptides first (BPC-157/TB-500 for Baar protocol, Semaglutide for sarcopenia risk, Ipamorelin for GH recovery)
- semaglutide-1 (STEP-1 RCT) is the only Phase 3 RCT in the section — framed explicitly as gold-standard evidence
- semaglutide-2 (Locatelli 2024) wired with both crossReference and muscle-loss safety framing — "resistance training non-optional"
- Epithalon studies note single-research-group provenance (Khavinson, St. Petersburg) and absent independent replication — honest framing matches Phase 1 WHM autophagy pattern
- practicalApplication left unchanged per plan spec — Plan 03 will update with full cross-reference text

## Deviations from Plan

None - plan executed exactly as written.

## Issues Encountered

None — the study objects in 03-RESEARCH.md were pre-formatted TypeScript and inserted directly. TypeScript compiled cleanly on first attempt.

## User Setup Required

None - no external service configuration required.

## Next Phase Readiness

- Plan 03-02 is ready to append: GHK-Cu (2-3 studies), DSIP (2), MOTS-c (2), 5-Amino-1MQ (1) — verified PMIDs in 03-RESEARCH.md
- Plan 03-03 can update practicalApplication after both study batches are complete
- All exercise-protocol cross-references from batch 1 are wired and confirmed present

---
*Phase: 03-peptide-science*
*Completed: 2026-03-19*
